A novel mutation in PTEN in anaplastic thyroid carcinoma: A case report

Zhao,Yanli

doi:10.3892/br.2024.1815

A novel mutation in PTEN in anaplastic thyroid carcinoma: A case report

Authors:
- Yanli Zhao
View Affiliations

Affiliations: Department of Pathology, Linfen Central Hospital, Linfen, Shanxi 041099, P.R. China
Published online on: July 2, 2024 https://doi.org/10.3892/br.2024.1815
Article Number: 127
Copyright: © Zhao . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anaplastic thyroid cancer (ATC) is a rare disease with a poor prognosis and accounts for a high proportion of thyroid cancer deaths. The present study reported on a 56‑year‑old male patient with ATC and examined the clinical manifestations, pathological features, differential diagnosis and genetic mutations. Immunohistochemical analysis showed positivity for vimentin, Ki‑67 and cytokeratin in the tumor specimen. In addition, pathological mitotic figures of tumor cells and intra‑lymph node metastasis were observed. Genetic analysis revealed the presence of a novel mutation (c.388C>T, p.R130X) in exon 5 of the phosphatase and tensin homolog (PTEN) gene, which was first detected in ATC. Gene conservation analysis showed that R130 is a highly conserved amino acid. Protein structure model predictions implied that p.R130X mutation results in a severe defect of the C2 domain and the TAD domain of PTEN, which may be a reason for the high malignancy of the tumor. The present case report highlights a novel mutation of PTEN in ATC, which expands the molecular spectrum of PTEN and further underlines the importance of PTEN.

View Figures

View References

1	Graceffa G, Salamone G, Contino S, Saputo F, Corigliano A, Melfa G, Proclamà MP, Richiusa P, Mazzola S, Tutino R, et al: Risk factors for anaplastic thyroid carcinoma: A case series from a tertiary referral center for thyroid surgery and literature analysis. Front Oncol. 12(948033)2022.PubMed/NCBI View Article : Google Scholar
2	Rao SN and Smallridge RC: Anaplastic thyroid cancer: An update. Best Pract Res Clin Endocrinol Metab. 37(101678)2023.PubMed/NCBI View Article : Google Scholar
3	Talbott I and Wakely PE Jr: Undifferentiated (anaplastic) thyroid carcinoma: Practical immunohistochemistry and cytologic look-alikes. Semin Diagn Pathol. 32:305–310. 2015.PubMed/NCBI View Article : Google Scholar
4	Jannin A, Escande A, Al Ghuzlan A, Blanchard P, Hartl D, Chevalier B, Deschamps F, Lamartina L, Lacroix L, Dupuy C, et al: Anaplastic thyroid carcinoma: An Update. Cancers (Basel). 14(1061)2022.PubMed/NCBI View Article : Google Scholar
5	de Ridder M, Nieveen van Dijkum E, Engelsman A, Kapiteijn E, Klumpen HJ and Rasch CRN: Anaplastic thyroid carcinoma: A nationwide cohort study on incidence, treatment and survival in the Netherlands over 3 decades. Eur J Endocrinol. 183:203–209. 2020.PubMed/NCBI View Article : Google Scholar
6	Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S, Cognetti F and Ciuffreda L: PTEN: Multiple functions in human malignant tumors. Front Oncol. 5(24)2015.PubMed/NCBI View Article : Google Scholar
7	Haddadi N, Lin Y, Travis G, Simpson AM, Nassif NT and McGowan EM: PTEN/PTENP1: ‘Regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy. Mol Cancer. 17(37)2018.PubMed/NCBI View Article : Google Scholar
8	Cain RJ and Ridley AJ: Phosphoinositide 3-kinases in cell migration. Biol Cell. 101:13–29. 2009.PubMed/NCBI View Article : Google Scholar
9	Ward PS and Thompson CB: Signaling in control of cell growth and metabolism. Cold Spring Harb Perspect Biol. 4(a006783)2012.PubMed/NCBI View Article : Google Scholar
10	Yehia L, Keel E and Eng C: The clinical spectrum of PTEN Mutations. Annu Rev Med. 71:103–116. 2020.PubMed/NCBI View Article : Google Scholar
11	Fraser MM, Zhu X, Kwon CH, Uhlmann EJ, Gutmann DH and Baker SJ: Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res. 64:7773–7779. 2004.PubMed/NCBI View Article : Google Scholar
12	Nagy R, Ganapathi S, Comeras I, Peterson C, Orloff M, Porter K, Eng C, Ringel MD and Kloos RT: Frequency of germline PTEN mutations in differentiated thyroid cancer. Thyroid. 21:505–510. 2011.PubMed/NCBI View Article : Google Scholar
13	Rustad CF, Bjornslett M, Heimdal KR, Maehle L, Apold J and Moller P: Germline PTEN mutations are rare and highly penetrant. Hered Cancer Clin Pract. 4:177–185. 2006.PubMed/NCBI View Article : Google Scholar
14	Bandargal S, Rajab M, Forest VI, Pusztaszeri MP, Hier MP, da Silva SD and Payne RJ: Characteristics of PTEN mutation in thyroid tumours: A retrospective chart review. Cancers (Basel). 15(1575)2023.PubMed/NCBI View Article : Google Scholar
15	Zhou J, Song Y, Zhan W, Wei X, Zhang S, Zhang R, Gu Y, Chen X, Shi L, Luo X, et al: Thyroid imaging reporting and data system (TIRADS) for ultrasound features of nodules: Multicentric retrospective study in China. Endocrine. 72:157–170. 2021.PubMed/NCBI View Article : Google Scholar
16	Zhang Y, Zheng H, Xu M, Maeda N, Tsunedomi R, Kishi H, Nagano H and Kobayashi S: Fyn-Mediated paxillin tyrosine 31 phosphorylation regulates migration and invasion of breast cancer cells. Int J Mol Sci. 24(15980)2023.PubMed/NCBI View Article : Google Scholar
17	Dum D, Menz A, Volkel C, De Wispelaere N, Hinsch A, Gorbokon N, Lennartz M, Luebke AM, Hube-Magg C, Kluth M, et al: Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers. Exp Mol Pathol. 126(104762)2022.PubMed/NCBI View Article : Google Scholar
18	Berr AL, Wiese K, Dos Santos G, Koch CM, Anekalla KR, Kidd M, Davis JM, Cheng Y, Hu YS and Ridge KM: Vimentin is required for tumor progression and metastasis in a mouse model of non-small cell lung cancer. Oncogene. 42:2074–2087. 2023.PubMed/NCBI View Article : Google Scholar
19	Davey MG, Hynes SO, Kerin MJ, Miller N and Lowery AJ: Ki-67 as a prognostic biomarker in invasive breast cancer. Cancers (Basel). 13(4455)2021.PubMed/NCBI View Article : Google Scholar
20	Hu X, He S, Jiang X, Wei P, Zhou X, Shi Z, Li X, Lu J, Zhao H, Wei B and Jin M: Reticular fibre structure in the differential diagnosis of parathyroid neoplasms. Diagn Pathol. 18(79)2023.PubMed/NCBI View Article : Google Scholar
21	Chen X, Schulz-Trieglaff O, Shaw R, Barnes B, Schlesinger F, Källberg M, Cox AJ, Kruglyak S and Saunders CT: Manta: Rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 32:1220–1222. 2016.PubMed/NCBI View Article : Google Scholar
22	Nagaiah G, Hossain A, Mooney CJ, Parmentier J and Remick SC: Anaplastic thyroid cancer: A review of epidemiology, pathogenesis, and treatment. J Oncol. 2011(542358)2011.PubMed/NCBI View Article : Google Scholar
23	Luongo F, Colonna F, Calapa F, Vitale S, Fiori ME and De Maria R: PTEN Tumor-Suppressor: The dam of stemness in cancer. Cancers (Basel). 11(1076)2019.PubMed/NCBI View Article : Google Scholar
24	Leslie NR and Longy M: Inherited PTEN mutations and the prediction of phenotype. Semin Cell Dev Biol. 52:30–38. 2016.PubMed/NCBI View Article : Google Scholar
25	Song MS, Salmena L and Pandolfi PP: The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 13:283–296. 2012.PubMed/NCBI View Article : Google Scholar
26	Bonneau D and Longy M: Mutations of the human PTEN gene. Hum Mutat. 16:109–122. 2000.PubMed/NCBI View Article : Google Scholar
27	Dillon LM and Miller TW: Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets. 15:65–79. 2014.PubMed/NCBI View Article : Google Scholar
28	Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, et al: Highly accurate protein structure prediction with AlphaFold. Nature. 596:583–589. 2021.PubMed/NCBI View Article : Google Scholar
29	Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, Yuan D, Stroe O, Wood G, Laydon A, et al: AlphaFold protein structure database: Massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 50(D1):D439–D444. 2022.PubMed/NCBI View Article : Google Scholar
30	Danielsen SA, Lind GE, Bjornslett M, Meling GI, Rognum TO, Heim S and Lothe RA: Novel mutations of the suppressor gene PTEN in colorectal carcinomas stratified by microsatellite instability- and TP53 mutation-status. Hum Mutat. 29:E252–E262. 2008.PubMed/NCBI View Article : Google Scholar
31	Kim RH, Wang X, Evans AJ, Campbell SC, Nguyen JK, Farncombe KM and Eng C: Early-onset renal cell carcinoma in PTEN harmatoma tumour syndrome. NPJ Genom Med. 5(40)2020.PubMed/NCBI View Article : Google Scholar
32	Pistorius S, Klink B, Pablik J, Rump A, Aust D, Garzarolli M, Schröck E and Schackert HK: An unusual case of Cowden syndrome associated with ganglioneuromatous polyposis. Hered Cancer Clin Pract. 14(11)2016.PubMed/NCBI View Article : Google Scholar
33	Fusco N, Sajjadi E, Venetis K, Gaudioso G, Lopez G, Corti C, Rocco EG, Criscitiello C, Malapelle U and Invernizzi M: PTEN alterations and their role in cancer management: Are we making headway on precision medicine? Genes (Basel). 11(719)2020.PubMed/NCBI View Article : Google Scholar
34	Owen S, Alken S, Alshami J, Guiot MC, Kavan P, Reardon DA, Muanza T, Gibson N, Pemberton K, Solca F, et al: Genomic analysis of tumors from patients with glioblastoma with long-term response to afatinib. Onco Targets Ther. 15:367–380. 2022.PubMed/NCBI View Article : Google Scholar
35	Lee Y and Oh YL: Thyroid pathology, a clue to PTEN hamartoma tumor syndrome. J Pathol Transl Med. 57:178–183. 2023.PubMed/NCBI View Article : Google Scholar